CLINICAL NEWS

Is high-cost U.S. cancer care worth 'value of hope' for patients?

A cluster of recently published articles might help policy-makers, patients, and providers decide when a high-cost treatment is “worth” the expense in terms of delivering better health to patients. » More

Fluoroquinolones may increase risk of retinal detachment

Oral fluoroquinolones, one of the most commonly prescribed classes of antibiotics, may increase a person’s risk for developing a retinal detachment, according to a study published April 4 in JAMA. » More

Two antidepressants decrease depression in Parkinson’s patients, study finds

Certain antidepressants decrease depression in people with Parkinson’s disease without worsening their motor problems, according to a new study published in Neurology. » More

CONTINUING EDUCATION

The impact of electronic health records on pharmacy practice

E-prescribing, a paperless, real-time transmission of data, places pharmacists squarely within the healthcare technology team.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

FDA ACTIONS

FDA approves treatment for Parkinson's, RLS

FDA approved rotigotine transdermal system (Neupro, UCB) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease and as a treatment for moderate-to-severe primary restless legs syndrome. » More

DRUG TRENDS

Study shows link between greater cost-sharing and higher hospitalization rates for asthmatic children

Greater cost-sharing of asthma medications led to higher hospitalization rates in children 5 years or older, according to a new study published in the March 28 issue of JAMA. » More

Like us on Facebook

Voices

•	Anticoagulation Update
•	JP at Large
•	View from the Zoo
•	Viewpoints
•	Regulatory & Legal

Meetings & Events

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.